品牌
生产厂家厂商性质
广州市所在地
痢疾阿米巴
痢疾阿米巴的病原体是entamebosis发生。痢疾阿米巴的营养阶段(营养体)住在大肠,形成包绕的阶段(囊肿)与粪便排泄。
营养体可以穿透肠壁,侵入肝脏及其他器官产生临床amebosis形式,zui常见的肠道amebosis和肝amebosis(阿米巴肝脓肿)。
临床症状可以开发zui早在感染后2 - 4周或无症状后几个月,甚至几年的时间。
以下肠道形式出现:
痢疾阿米巴感染发生在世界范围内,普遍在温暖的国家。在流行地区,在非洲、亚洲和南美洲70 - 90%的人口可以痢疾阿米巴的载体。感染是由囊肿从一个人传播到另一个由于传播成熟的囊肿和受污染的食品(果蔬),饮用水或粪便污染的手。苍蝇和蟑螂可以从粪便作为中介,囊肿excretor的食物。每年新发病例的数量估计在4800万年,约有70 000致命的结果(,1998)。
物种 | 感染的机制 | 症状 | 并发症 | 诊断 |
痢疾阿米巴 | 口周围的摄入、饮用水、食物 | 没有超过90%(无症状,肠道形式)出现大便,腹泻、败血症 | 腹部出血、结肠炎、肝脓肿、腹膜炎 | 显微镜临床血清学方法(超音波,电脑断层扫描等) |
感染的诊断则需要通过:
NovaLisa吗?痢疾阿米巴免疫球蛋白ELISA:
NovaLisa吗?痢疾阿米巴免疫球蛋白ELISA用于定性测定IgG-class抗体痢疾阿米巴在人类血清或血浆(柠檬酸)。
抗原:
纯化痢疾阿米巴Trophozoit抗原
具体的性能特征:
| Intraassay | Interassay | 灵敏度 | 特异性 | ||||
| n | 的意思是 | CV % | n | 目的 | CV % |
|
|
免疫球蛋白 | 7 | 0.609 | 2.1 | 6 | 0.604 | 3.9 | > 95% | > 95% |
订单信息:
ELISA | 的数量决定 | 产品编号 |
痢疾免疫球蛋白 | 96年 | ENTG0140 |
Entamoeba histolytica
Entamoeba histolytica is the causative agent of the worldwide occurring entamebosis. The vegetative stages (trophozoites) of Entamoeba histolytica live in the large intestine and form encysted stages (cysts) that are excreted with feces.
The trophozoites can penetrate into the intestinal wall and invade the liver and other organs to produce clinical forms of amebosis, most frequently intestinal amebosis and hepatic amebosis (amoebic liver abscess).
Clinical symptoms can develop as early as 2-4 weeks after infection or after asymptomatic periods of months or even years.
The following intestinal forms occur:
Infections of Entamoeba histolytica occur worldwide, prevalent in warmer countries. In endemic areas in Africa, Asia and Central and South America up to 70-90% of the population can be carriers of Entamoeba histolytica. The infection is transmitted by cysts from one human to another due to transmission of mature cysts with contaminated foods (fruit vegetables), drinking water or fecally contaminated hands. Flies and cockroaches can function as intermediaries by carrying cysts from the feces of an excretor to foods. Worldwide the annual number of new cases is estimated at 48 million, with about 70 000 lethal outcomes (WHO, 1998).
Species | Mechanism of Infection | Symptoms | Complications | Diagnostic |
Entamoeba histolytica | Peroral ingestion,drinking water, foods | With more than 90% no (asymptomatic, intestinal form)blood-tinged stools, diarrhea, sepsis | Abdominal bleeding, colitis,liver abscess, peritonitis | Microscopy Serology Clinical methods(Ultrasound, computer tomography, etc.) |
Infections may be diagnosed by:
NovaLisa? Entamoeba histolytica IgG ELISA:
The NovaLisa? Entamoeba histolytica IgG ELISA is intended for the qualitative determination of IgG-class antibodies against Entamoeba histolytica in human serum or plasma (citrate).
Antigens:
Purified Entamoeba histolytica Trophozoit antigens
Specific performance characteristics:
| Intraassay | Interassay | Sensitivity | Specificity | ||||
| n | Mean | CV% | n | Meam | CV% |
|
|
IgG | 7 | 0.609 | 2.1 | 6 | 0.604 | 3.9 | >95% | >95% |
Order information:
ELISA | Number of Determinations | Product Number |
Entamoeba IgG | 96 | ENTG0140 |